Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

24.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Where Will Moderna Be in 3 Years?
Via The Motley Fool
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
3M, Netflix And 3 Stocks To Watch Heading Into Tuesday
US stock futures trading higher on Tuesday. Stocks to watch: 3M, D.R. Horton, Moderna, United Airlines, Netflix. 
Via Benzinga
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
Is Moderna Stock a Buy?
Via The Motley Fool
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
Via The Motley Fool
Is Moderna a Bad-News Buy for 2025?
Via The Motley Fool
These Were the 5 Worst-Performing Stocks in the S&P 500 in 2024
Via The Motley Fool
Topics Stocks
Exposures US Equities
Moderna Announces Updates on Pandemic Influenza Program
Via ACCESS Newswire
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
Exposures Political
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
Via The Motley Fool
Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
Via Benzinga
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
Via The Motley Fool
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing
The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours. 
Via Benzinga
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?
Traders adopted a cautious approach on Monday as they awaited two critical inflation reports due later this week, seeking clarity on Federal Reserve interest rate policy. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
Via Benzinga
Moderna Stock Takes A 20% Hit
Moderna stock is now down close to 30% versus its YTD high. 
Via Talk Markets
Topics Stocks / Equities
Why Moderna Stock Just Crashed 21%
Via The Motley Fool
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Moderna Stock Sinks To Over 5-Year Low On $1B Sales Guidance Cut: Retail’s Shaken
The revised projection largely reflects declining COVID-19 vaccine demand, as fewer people seek boosters amid the ongoing shift to an endemic phase. 
Via Stocktwits
Exposures COVID-19
Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance
The company also had a setback for its CMV vaccine. 
Via Investor's Business Daily
Exposures COVID-19
Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives
Moderna targets ten product approvals by 2027 while cutting R&D costs by $1.1 billion. FY2024 revenue reached $3 billion-$3.1 billion, with $9.5B in cash reserves. 
Via Benzinga
MarketBeat Week in Review – 01/06 - 01/10
Stocks continued to slide after a hot jobs report sent bond yields higher, lowered expectations for future rate cuts, and keeps inflation and earnings in focus 
Via MarketBeat
Topics Bonds Economy Government
Exposures Debt Markets Interest Rates Political
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top ten worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
"Motley Fool Money" 2025 Stock Market Preview
New year, new market? Motley Fool analysts preview what's in store for investors in 2025, the companies they're excited to watch and the businesses they're worried about. 
Via The Motley Fool
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind. 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.